|
- FDA Extends Review of Tolebrutinib | National MS Society
Tolebrutinib — an oral BTK-inhibitor — would mark the first disease-modifying therapy specifically to treat non-relapsing secondary progressive MS The extension is the result of new analyses that were submitted during the review, which the FDA says warrants changes to the new drug application
- Press Room - Sanofi US News
Tolebrutinib is an investigational, oral, brain-penetrant Bruton’s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation, a key driver of disability progression in MS
- Sanofi provides update on tolebrutinib in primary progressive multiple . . .
Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape Standing at the intersection of neurology and immunoscience, Sanofi is focused on improving the lives of those living with serious neuro-inflammatory and neuro-degenerative conditions including MS, chronic
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib is an oral, brain-penetrant Bruton’s tyrosine kinase inhibitor that targets myeloid cells (including microglia) and B cells in both the periphery and central nervous system There
- Sanofi’s experimental MS therapy tolebrutinib suffers twin setbacks
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will be delayed again
- FDA starts review of Sanofis MS hope tolebrutinib
Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator
- Tolebrutinib: What is it and is it FDA approved? - Drugs. com
Current FDA approval status, regulatory history, and clinical trial results for tolebrutinib, an investigational treatment for non-relapsing secondary progressive multiple sclerosis from the development pipeline at Sanofi
- FDA accepts tolebrutinib for priority review for patients with MS
Tolebrutinib is an investigational, oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor specifically designed to target smoldering neuroinflammation
|
|
|